title: Prolonged cardiac xenograft survival is induced by intrathymic splenocyte injection.
abstract: The shortage of suitable human organs currently limits widespread utilization of clinical transplantation. Successful xenotransplantation could potentially eliminate the shortage of suitable organs for transplantation. The present study determines the effect of intrathymic donor spleen cell injection on the survival of cardiac xenografts performed without post-transplant immunosuppression. Wistar-Furth rats served as recipients of Lewis rat cardiac allografts or Golden Syrian hamster cardiac xenografts either with or without intrathymic donor spleen cell injection. Some xenograft cohorts were pretreated with four doses of cyclophosphamide prior to cardiac transplantation. Graft function was assessed by daily graft palpation and rejection was defined as cessation of graft function. Cardiac allograft median survival time (MST) was 8 days in untreated recipients. Pretreatment with intrathymic donor spleen cell injection led to essentially indefinite allograft survival (MST > 100 days). Control xenograft survival was 3 days with no significant prolongation seen when intrathymic donor spleen cell injection was performed (MST = 2.5 days). The addition of pulse-dose cyclophosphamide resulted in markedly prolonged xenograft survival (MST = 30 days) compared to control (P < 0.01) and to cyclophosphamide alone (MST = 9.5 days, P < 0.01). Cardiac xenografts undergo a vigorous rapid rejection. The time course of rejection was not altered by the intrathymic presence of donor cells under conditions which lead to indefinite survival of cardiac allografts. A brief period of pretransplant cyclophosphamide treatment markedly improved the success of the thymic tolerance protocol in xenografts. This finding suggests that temporary inhibition of humoral immunity may be permissive for the development of thymic tolerance to cell-mediated immunity in xenotransplants.
authors.affiliation: Department of Surgery, University of Maryland Medical Systems, Baltimore 21201.
authors.forename: C D
authors.initials: CD
authors.lastname: Sheffield
authors.forename: G A
authors.initials: GA
authors.lastname: Hadley
authors.forename: B M
authors.initials: BM
authors.lastname: Dirden
authors.forename: S T
authors.initials: ST
authors.lastname: Bartlett
mesh_terms: D000818:Animals; D017690:Cell Transplantation; D006224:Cricetinae; D003520:Cyclophosphamide / Q000494:pharmacology; D006085:Graft Survival / Q000187:drug effects; D016027:Heart Transplantation; D007267:Injections; D008297:Male; D008647:Mesocricetus; D051381:Rats; D011917:Rats, Inbred Lew; D011920:Rats, Inbred WF; D013154:Spleen / Q000166:cytology*; D013950:Thymus Gland / Q000503:physiopathology*; D013997:Time Factors; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous
chemical_list: D003520:Cyclophosphamide